For HCPs: Treatment approaches based on CheckMate-9ER

Please see Full Prescribing Information for CABOMETYX (cabozantinib): www.cabometyxh...
This video is intended for US healthcare professionals only.
Dr. Robert Alter and Dr. Arash Rezazadeh review the CheckMate-9ER clinical trial efficacy, safety and tolerability data. They discuss their treatment considerations for CABOMETYX + OPDIVO (nivolumab) across a hypothetical poor-risk patient case study.
Product information provided in these videos is intended only for US healthcare professionals. These videos are sponsored by Exelixis, Inc, and were developed in conjunction with Dr. Alter and Dr. Rezazadeh. Dr. Alter and Dr. Rezazadeh received a fee for participating in these videos. Their comments reflect their opinions and are not intended to constitute medical advice for individual patients. The case study details presented are hypothetical. Individual results may vary.
OPDIVO® and the related logo is a registered trademark of Bristol-Myers Squibb Company.